FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average	burden
ours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person *-					2. Issuer Name and Ticker or Trading Symbol										of Reportin	ng Person(s)	to Issuer				
Ahn Char		Reporting Person	_				ARMACE							-		all applicat	ole)				
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455					f Ea 015		Transactio	on (Mo	nth/Da	y/Ye	ear)		X_Director10% Owner Officer (give title below) Other (specify below)								
,		(Street)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	4. If Ame	endn	nent,	Date Origi	inal Fil	ed(Mont	h/Day	/Year)		_X_ Form f	iled by	One Reporting I	p Filing(Chec Person Reporting Persor		Line)			
ROCKVI (City	LLE, MD 2	(State)	(Zip)																		
		(State)	1	21.5												ficially Owi		la 31			
1.Title of S (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year)	2A. Deen Execution any (Month/I	n Da	ĺ	(Instr. 8)	ction	or Dis	pose	ed of (D) and 5)			Follov tion(s	,		6. Ownershi Form: Direct (D	of Ir Ben	eficial		
				`	J		Code	V	Amo	unt	(A) or (D)	Price			,		or Indirec (I) (Instr. 4)				
Common	Stock		01/08/2015				M		80,00	00	A \$	\$ 0.8	6,090,	000			D				
Common	Stock		01/08/2015				S(1)		80,00	00		\$ 0.9004 (2)	6,010,	000			D				
Common	Stock		01/09/2015				M		186,2	212	A 5	\$ 0.8	6,196,	212							
Common	Stock		01/09/2015				S ⁽¹⁾		186,2	212		\$ 0.9155 (3)	6,010,	000			D				
Common	Stock		01/12/2015				M		48,44	14	A 5	\$ 0.8	6,058,	144			D				
Common	Common Stock 01/12/2015		01/12/2015			S ⁽¹⁾		48,44	14		\$ 0.9137 (4)	6,010,000			D						
Common	Stock												500,00	0			I	By spo	use		
Reminder:	Report on a s	separate line for ea	ch class of securities	beneficia	ılly o	owne	d directly of	Per con	sons v	l in t	this fo	rm are n	ot requ	ired		d unless th		C 1474	1 (9-02)		
								forr	n disp	lays	a curi	rently va	alid OM	В со	ntrol numb	oer.					
			Table II -				ities Acqui						Owned								
1. Title of Derivative Security (Instr. 3)		3. Transaction Date (Month/Day/Year	3A. Deemed Execution Date, it any (Month/Day/Year	4. Transac Code	tion	5. N Der Sec Acq or I of (I	Number of ivative urities quired (A) Disposed D) ttr. 3, 4,	6. Dat Expira	e Exercation D	cisab ate	le and	7. Title of Unde Securiti	ies 3 and 4)			9. Number Derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	Owner Form Ouriva Securi Direct or Ind	rship of Hative (ty: (D) irect	11. Natu of Indire Benefic Owners (Instr. 4		
				Code	V	(A)	(D)	Date Exerc	isable l		ration	Title	or Nu	ount nber hares							
Stock Option (right to purchase)	\$ 0.8	01/08/2015		М			80,000	1	<u>6</u>	01/2	20/2015	Comm Stock		,000	\$ 0	783,807	7 D				
Stock Option (right to purchase)	\$ 0.8	01/09/2015		М			186,212	(<u>6)</u>	01/2	20/2015	Comm		5,212	\$ 0	597,595	5 D				

48,444

M

<u>(6)</u>

01/20/2015

Common

Stock

\$ 0

48,444

549,151

D

Reporting Owners

\$ 0.8

01/12/2015

Stock Option

(right to

purchase)

D (1 0 N /AU		Relationsh	ips	
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Ahn Chang Ho C/O REXAHN PHARMACEUTICALS, INC.				

15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X			
Signatures				
/s/ Tae Heum Jeong, as attorney-in-fact for Ch	ang Ho A	hn	01/12	2/2015
**Signature of Reporting Person			D	ate

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- (2) The price of \$0.9004 per share represents a weighted average of sales prices from \$0.90 to \$0.9098 per share. The reporting person undertakes to provide upon request of the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (3) The price of \$0.9155 per share represents a weighted average of sales prices from \$0.90 to \$0.945 per share. The reporting person undertakes to provide upon request of the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price of \$0.9137 per share represents a weighted average of sales prices from \$0.90 to \$0.9351 per share. The reporting person undertakes to provide upon request of the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (5) The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- (6) Options vested and became exercisable based on the following schedule: 300,000 on January 20, 2006, 300,000 on January 20, 2007, and 400,000 on January 20, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.